Adverse Effects of Delayed Transplant Listing Among Patients With Implantable Left Ventricular Assist Devices

Dardas, Todd; Cheng, Richard K.; Mahr, Claudius; Mokadam, Nahush A.; Smith, Jason W.; Aaronson, Keith D.; Pagani, Francis D.; Levy, Wayne C.

doi:10.1016/j.cardfail.2018.01.003

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One way to improve combined survival in BTT patients would be to increase bridging times and thereby extend cumulative survival. This approach was challenged by a recent report [11] and still requires more data on long-term survival in our patients.…”

Section: Discussionmentioning

confidence: 98%

“…Twenty patients needed only one readmission, 7 patients were re-hospitalized twice and 13 patients required more than two readmissions. Most common causes of readmission were non-pump related infection (19), gastrointestinal bleeding (23), right heart failure (13), and stroke (11). Pump malfunction requiring speed re-adjustment or controller exchange (n=9), driveline infection (n=8), and arrhythmia (n=4) were less frequent.…”

Section: Adverse Eventsmentioning

confidence: 99%

See 1 more Smart Citation

Outcome of patients receiving a continuous flow left ventricular assist device – a retrospective single center study

Kišš

Stark

Nykänen

et al. 2020

Scandinavian Cardiovascular Journal

View full text Add to dashboard Cite

Design: This was a single-center retrospective study. We describe our patient management in detail. The primary end-points were death, heart transplantation, or pump explant. Data were reported in accordance with the Interagency Registry for Mechanical Circulatory Support protocol. All patients receiving an assist device during the study period were included in the data analysis.Results: Mean patient age was 53±12 years at implantation and 85 % were male. Most patients suffered from dilated (48%), or ischemic (40%) cardiomyopathy. One-third of patients were bridged with venoarterial extracorporeal membrane oxygenation to assist device implantation. Implant strategy was bridge to transplant or bridge to decision in most patients (88 %). Mean follow-up time on pump was 529±467 days. Survival was 98%, 92%, 85%, 79% and 71% at 1, 3, 12, 24 and 36 months, respectively. Most common causes of death were multi-organ failure, right heart failure, or stroke. Only three patients (4%) had suspected pump thrombosis, two of which resolved with medical treatment and one resulting in death. Pump exchange or explant, were not performed in a single patient. Neurological events occurred in 18 %, non-disabling stroke in 8 %, and fatal stroke in 4% of the patients. The incidence of device-related infection was 10 %. Conclusions: Survival rates were good, although one third of patients were bridged with temporary circulatory support. We report a high level of freedom from pump thrombosis, fatal stroke, and driveline infection.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Adverse Eventsmentioning

confidence: 99%